KR102108149B1 - Ｈｉｖ 백신접종용 면역원 - Google Patents

Ｈｉｖ 백신접종용 면역원 Download PDF

Info

Publication number
KR102108149B1
KR102108149B1 KR1020147023946A KR20147023946A KR102108149B1 KR 102108149 B1 KR102108149 B1 KR 102108149B1 KR 1020147023946 A KR1020147023946 A KR 1020147023946A KR 20147023946 A KR20147023946 A KR 20147023946A KR 102108149 B1 KR102108149 B1 KR 102108149B1
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147023946A
Other languages
English (en)
Korean (ko)
Other versions
KR20140122735A (ko
Inventor
크리스티안 브란더
베아트리츠 모트 푸하다스
아누스카 라노
Original Assignee
에스테베 파마슈티칼스 에스에이
푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스테베 파마슈티칼스 에스에이, 푼다시오 프리바다 인스티튜트 데 레세르사 데 라 시다 - 카이사 filed Critical 에스테베 파마슈티칼스 에스에이
Publication of KR20140122735A publication Critical patent/KR20140122735A/ko
Application granted granted Critical
Publication of KR102108149B1 publication Critical patent/KR102108149B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147023946A 2012-01-27 2013-01-28 Ｈｉｖ 백신접종용 면역원 Active KR102108149B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
EP12382031.8 2012-01-27
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018840A Division KR102140778B1 (ko) 2012-01-27 2013-01-28 Ｈｉｖ 백신접종용 면역원

Publications (2)

Publication Number Publication Date
KR20140122735A KR20140122735A (ko) 2014-10-20
KR102108149B1 true KR102108149B1 (ko) 2020-05-12

Family

ID=47603800

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147023946A Active KR102108149B1 (ko) 2012-01-27 2013-01-28 Ｈｉｖ 백신접종용 면역원
KR1020197018840A Active KR102140778B1 (ko) 2012-01-27 2013-01-28 Ｈｉｖ 백신접종용 면역원

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197018840A Active KR102140778B1 (ko) 2012-01-27 2013-01-28 Ｈｉｖ 백신접종용 면역원

Country Status (16)

Country Link
US (4) US9988425B2 (enExample)
EP (3) EP2620446A1 (enExample)
JP (2) JP6306514B2 (enExample)
KR (2) KR102108149B1 (enExample)
CN (2) CN110372798A (enExample)
AU (2) AU2013213564B2 (enExample)
BR (1) BR112014018396B1 (enExample)
CA (1) CA2862172C (enExample)
ES (1) ES2932407T3 (enExample)
IL (2) IL233771B (enExample)
IN (1) IN2014DN06164A (enExample)
MX (2) MX358711B (enExample)
NZ (3) NZ734689A (enExample)
RU (2) RU2648791C2 (enExample)
WO (1) WO2013110818A2 (enExample)
ZA (1) ZA201405204B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US10072046B2 (en) * 2014-03-21 2018-09-11 Nutech Ventures Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CN114828884A (zh) * 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
WO2020237027A1 (en) * 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
CR20230312A (es) 2021-01-14 2023-08-31 Gilead Sciences Inc Vacunas contra el vih y métodos de uso
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6858712B1 (en) 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
PL192784B1 (pl) 1994-12-24 2006-12-29 Univ Cambridge Tech Zastosowanie kwasu nukleinowego
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CN1233187A (zh) 1996-08-09 1999-10-27 病毒技术公司 HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
BR0016510A (pt) * 1999-12-23 2002-08-27 Medical Res Council Aperfeçoamentos em ou relacionados as respostas imunes ao hiv
FR2803307A1 (fr) 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
AU5929101A (en) 2000-04-28 2001-11-12 Us Gov Health & Human Serv Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
IL160809A0 (en) 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
DE60325838D1 (de) 2002-03-19 2009-03-05 Glaxo Group Ltd Imidazoquinolinamine als adjuvantien für hiv dna vakzine
RU2238946C2 (ru) 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
EP1506223B1 (en) 2002-05-16 2005-11-16 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
NZ544011A (en) 2003-06-10 2009-02-28 Univ Melbourne Immunomodulating compositions uses therefor and processes for their production
CN102010463A (zh) 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
JP2007534302A (ja) * 2003-09-24 2007-11-29 オクソン セラピュティクス リミテッド Ｈｉｖ医薬
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
JP5122983B2 (ja) 2005-02-24 2013-01-16 メディカル リサーチ カウンシル Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
BRPI0613025A2 (pt) * 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
KR20080106467A (ko) 2006-03-10 2008-12-05 펩트셀 리미티드 Ｈｉｖ 조절 또는 보조 단백질의 펩타이드, 그 조성물 및 이용 방법
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
CA2670804A1 (en) 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
WO2008142479A2 (en) 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8198082B2 (en) 2007-03-28 2012-06-12 Hiroshima University Method of determining chicken embryonic stem cells
AU2008246139B2 (en) * 2007-04-26 2013-11-21 Merck Sharp & Dohme Llc Synthetic expression vectors for insect cells
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
BRPI0821998A2 (pt) 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd composições de imunomodulação e usos para a mesma.
JP5984388B2 (ja) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
ES2699685T3 (es) 2008-11-18 2019-02-12 Beth Israel Deaconess Medical Ct Inc Vacunas antivíricas con inmunogenicidad celular mejorada
US20120308593A1 (en) 2009-09-17 2012-12-06 Sanofi Pasteur, Inc. Immunological Compositions for HIV
EA201270108A1 (ru) 2009-10-08 2012-08-30 Бавариан Нордик А/С Формирование полиспецифического t-клеточного ответа против вич у человека
EP2488649B1 (en) 2009-10-16 2019-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011082422A2 (en) 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
CN103370333A (zh) 2010-11-10 2013-10-23 埃斯特韦实验室有限公司 高免疫原性hiv p24序列
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2020237027A1 (en) 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
CN114828884A (zh) 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment

Also Published As

Publication number Publication date
CA2862172C (en) 2023-07-18
JP6749357B2 (ja) 2020-09-02
EP4163290A1 (en) 2023-04-12
NZ723229A (en) 2019-03-29
BR112014018396A2 (enExample) 2017-06-20
KR20140122735A (ko) 2014-10-20
US11919926B2 (en) 2024-03-05
US9988425B2 (en) 2018-06-05
NZ628756A (en) 2016-12-23
RU2018104969A (ru) 2019-02-22
JP6306514B2 (ja) 2018-04-04
EP2620446A1 (en) 2013-07-31
IL233771A0 (en) 2014-09-30
IL268629B (en) 2021-06-30
US20190055289A1 (en) 2019-02-21
JP2018102314A (ja) 2018-07-05
RU2721274C2 (ru) 2020-05-18
AU2018203264A1 (en) 2018-05-31
BR112014018396B1 (pt) 2023-03-21
RU2648791C2 (ru) 2018-04-02
AU2013213564A1 (en) 2014-09-04
WO2013110818A3 (en) 2013-11-07
WO2013110818A2 (en) 2013-08-01
US20180170971A1 (en) 2018-06-21
CN110372798A (zh) 2019-10-25
BR112014018396A8 (pt) 2017-07-11
KR20190085552A (ko) 2019-07-18
CA2862172A1 (en) 2013-08-01
RU2018104969A3 (enExample) 2019-02-22
MX2014009091A (es) 2014-11-10
MX2018010483A (es) 2020-09-02
EP2807185B1 (en) 2022-09-14
CN104080800A (zh) 2014-10-01
ZA201405204B (en) 2015-10-28
NZ734689A (en) 2022-09-30
AU2013213564B2 (en) 2018-03-29
IN2014DN06164A (enExample) 2015-08-21
RU2014135053A (ru) 2016-03-27
IL268629A (en) 2019-10-31
HK1204632A1 (en) 2015-11-27
US11325946B2 (en) 2022-05-10
US20150050310A1 (en) 2015-02-19
ES2932407T3 (es) 2023-01-18
US10815278B2 (en) 2020-10-27
KR102140778B1 (ko) 2020-08-06
JP2015509707A (ja) 2015-04-02
EP2807185A2 (en) 2014-12-03
MX358711B (es) 2018-08-31
CN104080800B (zh) 2019-08-27
AU2018203264B2 (en) 2019-07-11
IL233771B (en) 2019-08-29
US20210246172A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
KR102108149B1 (ko) Ｈｉｖ 백신접종용 면역원
EP1035865B1 (en) Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
HK40016170A (en) Immunogens for hiv vaccination
HK1204632B (en) Immunogens for hiv vaccination
EP2517726A2 (en) Lentivirus vaccine based on the recombinant viral vaccine against yellow fever

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160706

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171024

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181030

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181030

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190628

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190530

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190130

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20171024

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190729

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20200130

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190628

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190530

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190130

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171024

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200429

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240319

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250317

Start annual number: 6

End annual number: 6